Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,681 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Synthesis and evaluation of novel orally active p53-MDM2 interaction inhibitors.
Miyazaki M, Naito H, Sugimoto Y, Yoshida K, Kawato H, Okayama T, Shimizu H, Miyazaki M, Kitagawa M, Seki T, Fukutake S, Shiose Y, Aonuma M, Soga T. Miyazaki M, et al. Among authors: sugimoto y. Bioorg Med Chem. 2013 Jul 15;21(14):4319-31. doi: 10.1016/j.bmc.2013.04.056. Epub 2013 Apr 30. Bioorg Med Chem. 2013. PMID: 23685175
Identification of trans-4-[1-[[7-fluoro-2-(1-methyl-3-indolyl)-6-benzoxazolyl]acetyl]-(4S)-fluoro-(2S)-pyrrolidinylmethoxy]cyclohexanecarboxylic acid as a potent, orally active VLA-4 antagonist.
Setoguchi M, Iimura S, Sugimoto Y, Yoneda Y, Chiba J, Watanabe T, Muro F, Iigo Y, Takayama G, Yokoyama M, Taira T, Aonuma M, Takashi T, Nakayama A, Machinaga N. Setoguchi M, et al. Among authors: sugimoto y. Bioorg Med Chem. 2012 Feb 1;20(3):1201-12. doi: 10.1016/j.bmc.2011.12.045. Epub 2011 Dec 30. Bioorg Med Chem. 2012. PMID: 22261021
A novel, potent, and orally active VLA-4 antagonist with good aqueous solubility: trans-4-[1-[[2-(5-Fluoro-2-methylphenylamino)-7-fluoro-6-benzoxazolyl]acetyl]-(5S)-[methoxy(methyl)amino]methyl-(2S)-pyrrolidinylmethoxy]cyclohexanecarboxylic acid.
Setoguchi M, Iimura S, Sugimoto Y, Yoneda Y, Chiba J, Watanabe T, Muro F, Iigo Y, Takayama G, Yokoyama M, Taira T, Aonuma M, Takashi T, Nakayama A, Machinaga N. Setoguchi M, et al. Among authors: sugimoto y. Bioorg Med Chem. 2013 Jan 1;21(1):42-61. doi: 10.1016/j.bmc.2012.11.003. Epub 2012 Nov 10. Bioorg Med Chem. 2013. PMID: 23218775
Discovery of trans-4-[1-[[2,5-Dichloro-4-(1-methyl-3-indolylcarboxamido)phenyl]acetyl]-(4S)-methoxy-(2S)-pyrrolidinylmethoxy]cyclohexanecarboxylic acid: an orally active, selective very late antigen-4 antagonist.
Muro F, Iimura S, Sugimoto Y, Yoneda Y, Chiba J, Watanabe T, Setoguchi M, Iigou Y, Matsumoto K, Satoh A, Takayama G, Taira T, Yokoyama M, Takashi T, Nakayama A, Machinaga N. Muro F, et al. Among authors: sugimoto y. J Med Chem. 2009 Dec 24;52(24):7974-92. doi: 10.1021/jm901154c. J Med Chem. 2009. PMID: 19891440
Clinical characteristics in adolescents and young adults with polycythemia vera and essential thrombocythemia in Japan.
Sugimoto Y, Nagaharu K, Ohya E, Ohishi K, Tawara I, Ito T, Gotoh A, Nakamae M, Kimura F, Koike M, Kirito K, Wada H, Usuki K, Tanaka T, Mori T, Wakita S, Saito TI, Saito AM, Shimoda K, Kurokawa T, Tomita A, Edahiro Y, Hashimoto Y, Kiyoi H, Akashi K, Matsumura I, Takenaka K, Komatsu N. Sugimoto Y, et al. Int J Hematol. 2024 Oct 28. doi: 10.1007/s12185-024-03862-5. Online ahead of print. Int J Hematol. 2024. PMID: 39467899
1,681 results